Literature DB >> 1109702

Blood substitutes.

E A Moffitt.   

Abstract

Substitutes for whole blood include blood fractions such as plasma, serum albumin and other fluids of various kinds which are not derived from blood but are used as plasma volume expanders; these, include the usual crystaloid intravenous solutions. Since in comparison to blood far more of these later solutions are given intravenously, a thorough knowledge of plasma volume expanders is essential. The first use of such expanders in human patients was by Hogan in 1915. He used colloidal gelatin and noted an improvement in blood pressure in shock. In 1945, Gronwall and Ingelman advocated the use of dextran in shock. The reguirements for an acceptable plasma substitute are: a satisfactory colloidal osmotic pressure, constand composition at reasonable cost, a viscosity suitable for intravenous administration, stability in prolonged storage at variable temperatures, and sterilization by autoclaving. Such substances must be either fully excreted or metabolized, and must cause no early or late tissue damage. They must be non-antigenic and pyrogen free. They must cause no change in the blood such as haemolysis, R.B.C. agglutination, increased sedimentation rate and no impairment of haemostasis. The presently available plasma expanders include blood derivatives (plasma, albumin), modified protein (gelatin, oxypolygelatin), polymerized carbohydrates (dextran) and plastics (polyvinyl pyrrolidone-PVP). All these substances expand plasma volume, decrease haematocrit and plasma proteins, increase sedimentation rate and blood pressure. Dextran, PVP and geletin do not alter hepatic function. Dextran and gelatin have no deleterious effects on renal function. Features of the clinically used plasma expanders are: 1. Fresh Frozen Plasma Fresh frozen plasma contains all clotting factors except platelets. The risk of the transmission of hepatitis is present as it is with whole blood. 2. Plasma Protein Fractions Plasma protein fractions are free of hepatitis virus, but may cause arteriolar dilatation and hypotension. 3. Serum Albumin Serum albumin is a concentrated blood protein fraction. It is salt poor, stable and does not transmit the virus of hepatitis. Since it has a high oncotic pressure it is necessary to give significant quantities of clear fluids with it. It is expensive, scarce, and dilutes the clotting factors. It is, however, a first choice for emergency treatment of shock; 4. Dextran The dextrans may be of medium or low molecular weight. They are inexpensive and readily available, and do not transmit the virus of hepatitis. In large amounts they cause a coagulation defect and may be antigenic. Continued.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1109702     DOI: 10.1007/bf03004814

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  16 in total

1.  Influence of low viscous dextran on the hemostatic mechanism.

Authors:  L E GELIN; K KORSAN-BENGTSEN; J YGGE; B ZEDERFELDT
Journal:  Acta Chir Scand       Date:  1961-11

2.  Preparation of a stable human plasma protein solution.

Authors:  D J MULFORD; E H MEALEY; L D WELTON
Journal:  J Clin Invest       Date:  1955-07       Impact factor: 14.808

3.  Metabolic and hemodynamic changes induced by the prolonged administration of dextran.

Authors:  J R JAENIKE; C WATERHOUSE
Journal:  Circulation       Date:  1955-01       Impact factor: 29.690

4.  INTRAVENOUS INJECTION IN WOUND SHOCK: Abstract of the Oliver-Sharpey Lectures delivered before the Royal College of Physicians on April 30th and May 2nd, 1918.

Authors:  W M Bayliss
Journal:  Br Med J       Date:  1918-05-18

5.  The effect of the intravenous administration of dextran on cardiac output and other circulatory dynamics.

Authors:  A C WITHAM; J W FLEMING; W L BLOOM
Journal:  J Clin Invest       Date:  1951-09       Impact factor: 14.808

6.  Plasmosan. A synthetic substitute for plasma.

Authors:  W R THROWER; H CAMPBELL
Journal:  Lancet       Date:  1951-05-19       Impact factor: 79.321

7.  Effects of intravenously administered solutions on electrolytes and energy substrates during surgery.

Authors:  E A Moffitt; N Schnelle; R Rodriguez; R A Lee; E S Judd
Journal:  Can Anaesth Soc J       Date:  1974-05

8.  Hypotension due to 5 per cent plasma protein fractions.

Authors:  J H Bland; M B Lavier; E Lowenstein
Journal:  N Engl J Med       Date:  1972-01-13       Impact factor: 91.245

9.  Dextrans, their use in surgery and medicine, with emphasis on the low molecular weight fractions.

Authors:  M Atik
Journal:  Anesthesiology       Date:  1966 Jul-Aug       Impact factor: 7.892

10.  Presently useful plasma volume expanders.

Authors:  A Kliman
Journal:  Anesthesiology       Date:  1966 Jul-Aug       Impact factor: 7.892

View more
  3 in total

Review 1.  Recent Developments in Magnetic Diagnostic Systems.

Authors:  Hakho Lee; Tae-Hyun Shin; Jinwoo Cheon; Ralph Weissleder
Journal:  Chem Rev       Date:  2015-08-10       Impact factor: 60.622

2.  Effect of N-Vinyl-2-Pyrrolidone (NVP), a Bromodomain-Binding Small Chemical, on Osteoblast and Osteoclast Differentiation and Its Potential Application for Bone Regeneration.

Authors:  Viviane A Klemmer; Nupur Khera; Barbara M Siegenthaler; Indranil Bhattacharya; Franz E Weber; Chafik Ghayor
Journal:  Int J Mol Sci       Date:  2021-10-13       Impact factor: 5.923

Review 3.  Activity of Povidone in Recent Biomedical Applications with Emphasis on Micro- and Nano Drug Delivery Systems.

Authors:  Ewelina Waleka; Zbigniew Stojek; Marcin Karbarz
Journal:  Pharmaceutics       Date:  2021-05-04       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.